- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The FDA has begun to regulate the market for obesity medications, reflecting a broader trend in pharmaceutical oversight.
Rhythm Pharmaceuticals' Setmelanotide was authorized for specific obesity cases by the FDA and European Commission.
8 reports, 5 independent
Updated Aug 26
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 8
- Developments
- 2
- Repetition
- 88%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Rhythm Pharmaceuticals' Setmelanotide was authorized for specific obesity cases by the FDA and European Commission.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Christian Roth was instrumental in the trial planning phase for Rhythm Pharmaceuticals, Inc.'s product.Sub-event
Setmelanotide received authorization for obesity and hunger control.1 source
Keep exploring
The entities involved
- FDA
-
European Commission
executive branch of the European Union
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA approval enables commercial opportunity involving CBRE Group.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
Coverage
Newest first; wire copies grouped- capitolfax.com
- manilatimes.net
- Insider MonkeyCitizens JMP Keeps Market Outperform Rating on Rhythm Pharmaceuticals (RYTM) Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the 10 Hot Mid Cap Stocks to Buy Now. On August 21, Citizens JMP reaf
- GlobeNewswireRhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopha
- Simply Wall St.FDA Priority Review for Setmelanotide in Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM) On August 20, 2025, Rhythm Pharmaceuticals announced that the FDA ac
- GlobeNewswireRhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity – U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA
- Unknown outlet
- Unknown outlet